Cariprazine (Vraylar)

SELF-ADMINISTRATION - ORAL

FDA Approved Indications:

  • Treatment of schizophrenia
  • Acute treatment of manic or mixed episodes associated with bipolar I disorder

Prior authorization criteria:

  • Diagnosis of schizophrenia or bipolar I disorder
  • 18 years of age or older
  • Patient has tried and failed at least 2 preferred atypical antipsychotics (e.g., risperidone, quetiapine, olanzapine, ziprasidone, aripiprazole)

Dosing:

  • Once daily (maximum dose is 6 mg/day)
    • Schizophrenia: starting dose 1.5mg/day, Recommended dose is 1.5 mg to 6 mg/day
    • Bipolar mania: starting dose 1.5mg/day, Recommended dose is 3 mg to 6 mg/day
  • Reduce Vraylar dosage if used with a strong CYP3A4 inhibitor
  • Concomitant use of Vraylar with a CYP3A4 inducer is not recommended

Approval:

  • 1 year

Last review date: June 27, 2017

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar